United States: with MoCRA, cosmetics compliance becomes a growth function

The Modernization of Cosmetics Regulation Act is, according to the FDA, the most significant expansion of its authority over cosmetics since 1938. Concerned manufacturers and processors must register their facilities and renew that registration every two years; the responsible person must list every marketed product, along with its ingredients, then update this information annually. As of June 30, 2026, the FDA recorded 16,398 active facilities and nearly 1.3 million active products.

For a foreign house, the mistake would be to treat these obligations as a file handed to a provider a few weeks before launch. MoCRA now ties formula, manufacturer, label, distribution and post-market surveillance more tightly together. Compliance becomes an ongoing operational process, and when well designed, an accelerator of growth rather than a brake.

Build a single source of truth for every product

A brand can no longer leave the formula with the lab, claims with marketing and labelling data in a separate file. Every reference needs a master file linking formula version, ingredients, manufacturing site, safety evidence, label artwork, open markets and filing status. Any change should trigger an impact review before production.

This discipline avoids the costliest gaps: a product listed under an outdated formula, non-compliant packaging, an unreported change of subcontractor, or a digital claim that differs from the label. It also eases expansion, since the same base data can feed distributors, e-commerce, customer service and regulators without rebuilding the information for every request.

Connect safety, complaints and recall decisions

Growth mechanically increases the number of customer returns. Brands must distinguish a sensory complaint from an adverse event, assess severity, identify the batch and escalate the information to the responsible person. Without a shared vocabulary between customer service, quality and distributors, weak signals stay scattered until they become a visible crisis.

An effective system fits in a short chain: a single intake form, escalation rules, a named owner, batch traceability and a periodic recall drill. The FDA now holds stronger authority, notably over registration and recall. A premium house must be able to decide quickly, document why it is acting, and communicate accurately without improvising under pressure.

Turn compliance into a portfolio filter

FDA registration is neither a product approval nor a marketing claim. The brand must resist the temptation to present a regulatory formality as a quality label. The real cost of maintaining each reference (data, safety, updates, stock and service), however, can inform range decisions.

Ahead of a US launch, a committee bringing together product, quality, finance and commercial teams should assess margin after compliance, claim risk and the ability to monitor the product over several years. Under-differentiated references then become visible before they clutter the portfolio. MoCRA can thus impose the discipline that international growth needs.

Back to the journal